Catabasis Joins Russell 3000® Index
June 29 2020 - 4:10PM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, announced today that it has joined the
broad-market Russell 3000® Index at the conclusion of the 2020
Russell Indexes annual reconstitution, effective after the US
market opened today.
Annual Russell indexes reconstitution captures the 4,000 largest
US stocks as of May 8, 2020, ranking them by total market
capitalization. FTSE Russell determines membership for its Russell
indexes primarily by objective market-capitalization rankings and
style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell’s US indexes. Russell indexes are
part of FTSE Russell, a leading global index provider.
For more information on the Russell 3000® Index and the Russell
indexes reconstitution, visit the “Russell Reconstitution” section
on the FTSE Russell website.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
About FTSE Russell:
FTSE Russell is a leading global index provider creating and
managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, style and strategies.
Covering 98% of the investable market, FTSE Russell indexes offer a
true picture of global markets, combined with the specialist
knowledge gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit www.ftserussell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200629005737/en/
Catabasis Investor and Media
Contact Andrea Matthews Catabasis Pharmaceuticals, Inc. T:
(617) 349-1971 amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024